Vyvgart Hytrulo CIDP denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues Non-Formulary Denials for Vyvgart Hytrulo in CIDP

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a subcutaneous FcRn-blocking therapy FDA-approved for adults with CIDP. Because it is a newer specialty biologic, many Blue Cross Blue Shield formularies either exclude it entirely or place it at a tier requiring additional authorization. A non-formulary denial does not mean the drug is medically inappropriate — it means the plan has not yet included it as a standard benefit, or has placed it behind a formulary exception process.

## Why This Denial Is Appealable

ACA §2719 and most state insurance laws require plans to maintain a formulary exception process. When no formulary alternative is clinically appropriate — because the patient has failed prior agents, has a documented intolerance, or has a clinical characteristic that makes alternatives unsuitable — the insurer must grant an exception. An FDA approval for the precise indication strengthens the exception request considerably.

## Federal Appeal Framework

• Formulary exception request: File this first (often before or alongside the formal appeal) using your prescriber's attestation that no formulary alternative is adequate.
• Internal appeal: If the exception is denied, you retain the right to a full internal appeal under ACA §2719 / ERISA §503.
• External review: A final adverse determination on a formulary exception is generally subject to independent external review. Preserve your external-review rights by requesting it within the timeframe shown on the denial letter (often around four months from the internal denial).
• Expedited track: Available when delay would seriously jeopardize health or the ability to regain maximum function.

## Documentation to Gather

1. Diagnosis confirmation — neurology records establishing CIDP diagnosis with objective findings. 2. Formulary alternative history — for each drug on the BCBS formulary that covers the same indication, document dates of use, doses attempted (per the prescriber's records), and the specific outcome: inadequate response, intolerance, contraindication, or clinical reason the alternative is unsuitable. 3. Why alternatives are inadequate — the prescriber's letter must explain, in clinical terms, why each formulary option is not appropriate for this specific patient. 4. Current clinical status — objective functional measures and disease severity as documented in the neurologist's notes. 5. FDA prescribing information — include a copy to demonstrate the drug's approved indication precisely matches the patient's diagnosis.

## Criteria-Mapping Structure

Pull the BCBS formulary exception policy and list each requirement. Alongside each requirement, cite the specific chart note, date, and clinician that satisfies it. For any formulary alternative the plan may argue is appropriate, document why the patient's clinical situation makes that alternative unsuitable — using the prescriber's own chart language, not just a general statement. Consult the FDA prescribing label and the insurer's current published policy for the exact criteria; do not rely on prior-year policy versions.